NO2658575T3 - - Google Patents
Info
- Publication number
- NO2658575T3 NO2658575T3 NO11807947A NO11807947A NO2658575T3 NO 2658575 T3 NO2658575 T3 NO 2658575T3 NO 11807947 A NO11807947 A NO 11807947A NO 11807947 A NO11807947 A NO 11807947A NO 2658575 T3 NO2658575 T3 NO 2658575T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10197122A EP2471554A1 (en) | 2010-12-28 | 2010-12-28 | Pharmaceutical formulation comprising a biopharmaceutical drug |
| PCT/EP2011/074181 WO2012089778A1 (en) | 2010-12-28 | 2011-12-28 | Pharmaceutical formulation comprising a biopharmaceutical drug |
| EP11807947.4A EP2658575B1 (en) | 2010-12-28 | 2011-12-28 | Pharmaceutical formulation comprising a biopharmaceutical drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2658575T3 true NO2658575T3 (zh) | 2018-04-14 |
Family
ID=43982272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO11807947A NO2658575T3 (zh) | 2010-12-28 | 2011-12-28 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9480743B2 (zh) |
| EP (2) | EP2471554A1 (zh) |
| JP (2) | JP5767340B2 (zh) |
| KR (1) | KR101808367B1 (zh) |
| CN (1) | CN103269718B (zh) |
| AR (2) | AR084627A1 (zh) |
| AU (1) | AU2011351414B2 (zh) |
| BR (1) | BR112013016770A2 (zh) |
| CA (1) | CA2822859C (zh) |
| DK (1) | DK2658575T3 (zh) |
| ES (1) | ES2659981T3 (zh) |
| HR (1) | HRP20171931T1 (zh) |
| HU (1) | HUE035707T2 (zh) |
| MX (1) | MX352245B (zh) |
| NO (1) | NO2658575T3 (zh) |
| PL (1) | PL2658575T3 (zh) |
| PT (1) | PT2658575T (zh) |
| RU (1) | RU2587056C2 (zh) |
| SI (1) | SI2658575T1 (zh) |
| TW (1) | TWI530295B (zh) |
| WO (1) | WO2012089778A1 (zh) |
| ZA (2) | ZA201304446B (zh) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2471554A1 (en) | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
| EP3912639A1 (en) | 2012-03-07 | 2021-11-24 | Cadila Healthcare Limited | Pharmaceutical formulations of tnf-alpha antibodies |
| US20130236505A1 (en) | 2012-03-09 | 2013-09-12 | Basf Se | Production Of Pharmaceutical Protective Coatings With Good Resistance In A Neutral Environment |
| EP2863951A1 (en) * | 2012-06-12 | 2015-04-29 | Boehringer Ingelheim International GmbH | Pharmaceutical formulation for a therapeutic antibody |
| EA201791717A1 (ru) | 2012-09-07 | 2018-03-30 | Кохерус Байосайенсис, Инк. | Стабильные водные составы адалимумаба |
| CA2895198A1 (en) * | 2012-12-20 | 2014-06-26 | Medimmune, Llc | Liquid antibody formulation with improved aggregation properties |
| CN103446583B (zh) * | 2013-03-21 | 2015-11-18 | 百奥泰生物科技(广州)有限公司 | 一种治疗TNF-α相关疾病的人抗体制剂 |
| SI3021833T2 (sl) * | 2013-07-19 | 2022-08-31 | Hexal Aktiengesellschaft | Postopki in formulacije, ki dopuščajo modulacijo imunskih odzivov, povezanih z dajanjem biofarmacevtskega zdravila |
| HUE029849T2 (en) | 2014-05-23 | 2017-04-28 | Ares Trading Sa | Liquid pharmaceutical composition |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| HUP1400510A1 (hu) | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| CN113474360A (zh) | 2019-02-18 | 2021-10-01 | 伊莱利利公司 | 治疗性抗体制剂 |
| WO2024133625A1 (en) | 2022-12-21 | 2024-06-27 | Formycon Ag | Formulations of anti-pd1 antibodies |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JP3179538B2 (ja) * | 1990-12-11 | 2001-06-25 | ノバルティス アクチエンゲゼルシャフト | 安定なヒトカルシトニンの水性溶液 |
| US20040120952A1 (en) * | 2000-08-07 | 2004-06-24 | Centocor, Inc | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5264142A (en) | 1991-11-25 | 1993-11-23 | Lever Brothers Company, Division Of Conopco, Inc. | Stabilization of peroxygen bleach in enzyme-containing heavy duty liquids |
| DK0859841T3 (da) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
| AU2440197A (en) * | 1996-04-18 | 1997-11-07 | Baxter International Inc. | Stabilization of therapeutic hemoglobin compositions |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| CN100518819C (zh) * | 2000-06-30 | 2009-07-29 | 阿斯比奥制药株式会社 | 含有人甲状旁腺激素的药物成分及含有该成分的用于鼻内给药的药物组合物 |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| JP5290489B2 (ja) * | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Ｉｇｇ抗体の安定な液体医薬製剤 |
| EP1446096A1 (en) * | 2001-11-13 | 2004-08-18 | The Procter & Gamble Company | Topical compositions containing enzymes stabilised with inhibitors |
| AU2003210405A1 (en) | 2002-03-05 | 2003-09-16 | Artemis Pharmaceuticals Gmbh | Inbred embryonic stem-cell derived mice |
| US20030204861A1 (en) | 2002-04-30 | 2003-10-30 | Madaiah Puttaraju | Transgenic animal model for spliceosome-mediated RNA trans-splicing |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US20040091490A1 (en) * | 2002-08-28 | 2004-05-13 | Robert Johnson | Stable pH optimized formulation of a modified antibody |
| WO2004039315A2 (en) * | 2002-10-29 | 2004-05-13 | Medical Nutrition Usa, Inc. | Method for treating wounds to promote healing |
| US20040101939A1 (en) * | 2002-11-22 | 2004-05-27 | Santora Ling C. | Method for reducing or preventing modification of a polypeptide in solution |
| EP1620072B1 (en) * | 2003-05-01 | 2008-03-26 | LTT Bio-Pharma Co., Ltd. | Zinc-containing sustained-release composition, its preparation, and method for producing the same |
| EP1688432B1 (en) * | 2003-10-09 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Igm high concentration stabilized solution |
| JPWO2005063291A1 (ja) * | 2003-12-25 | 2007-07-19 | 麒麟麦酒株式会社 | 抗体を含有する安定な水性医薬製剤 |
| US20080090753A1 (en) * | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| SV2008002394A (es) * | 2005-01-28 | 2008-02-08 | Wyeth Corp | Formulaciones liquidas estabilizadas de polipeptido ref. ahn- 072sv |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| GB0503337D0 (en) * | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
| KR101280273B1 (ko) | 2005-04-18 | 2013-07-15 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 안정화된 항-ｂ형 간염 바이러스 (ｈｂｖ) 항체 제형 |
| GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
| JP2009153392A (ja) * | 2007-12-25 | 2009-07-16 | Lion Corp | 液体経口用組成物 |
| NZ601913A (en) * | 2008-01-15 | 2014-02-28 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| PT2307457T (pt) * | 2008-06-25 | 2018-10-16 | Esbatech Alcon Biomed Res Unit | Anticorpos estáveis e solúveis que inibem o tnf |
| GB0818228D0 (en) * | 2008-10-06 | 2008-11-12 | Avecia Biolog Ltd | Purification process |
| EP2471554A1 (en) | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
-
2010
- 2010-12-28 EP EP10197122A patent/EP2471554A1/en not_active Withdrawn
-
2011
- 2011-12-28 CN CN201180062372.1A patent/CN103269718B/zh active Active
- 2011-12-28 WO PCT/EP2011/074181 patent/WO2012089778A1/en active Application Filing
- 2011-12-28 PL PL11807947T patent/PL2658575T3/pl unknown
- 2011-12-28 US US13/995,556 patent/US9480743B2/en active Active
- 2011-12-28 SI SI201131399T patent/SI2658575T1/en unknown
- 2011-12-28 RU RU2013133953/15A patent/RU2587056C2/ru active
- 2011-12-28 KR KR1020137016504A patent/KR101808367B1/ko active IP Right Grant
- 2011-12-28 BR BR112013016770A patent/BR112013016770A2/pt not_active Application Discontinuation
- 2011-12-28 MX MX2013007537A patent/MX352245B/es active IP Right Grant
- 2011-12-28 AU AU2011351414A patent/AU2011351414B2/en active Active
- 2011-12-28 NO NO11807947A patent/NO2658575T3/no unknown
- 2011-12-28 PT PT118079474T patent/PT2658575T/pt unknown
- 2011-12-28 HU HUE11807947A patent/HUE035707T2/en unknown
- 2011-12-28 JP JP2013546703A patent/JP5767340B2/ja active Active
- 2011-12-28 EP EP11807947.4A patent/EP2658575B1/en active Active
- 2011-12-28 AR ARP110104977A patent/AR084627A1/es not_active Application Discontinuation
- 2011-12-28 ES ES11807947.4T patent/ES2659981T3/es active Active
- 2011-12-28 DK DK11807947.4T patent/DK2658575T3/en active
- 2011-12-28 CA CA2822859A patent/CA2822859C/en not_active Expired - Fee Related
- 2011-12-28 TW TW100149158A patent/TWI530295B/zh active
-
2013
- 2013-06-06 ZA ZA2013/04446A patent/ZA201304446B/en unknown
- 2013-11-25 ZA ZA2013/08841A patent/ZA201308841B/en unknown
-
2015
- 2015-03-09 JP JP2015045482A patent/JP2015131832A/ja not_active Abandoned
-
2017
- 2017-12-13 HR HRP20171931TT patent/HRP20171931T1/hr unknown
-
2022
- 2022-01-18 AR ARP220100101A patent/AR124676A2/es unknown